Loading...
A328130 logo

Lunit Inc.KOSDAQ:A328130 Stock Report

Market Cap ₩1.2t
Share Price
₩38.15k
My Fair Value
n/a
1Y-20.9%
7D-13.5%
Portfolio Value
View

Lunit Inc.

KOSDAQ:A328130 Stock Report

Market Cap: ₩1.2t

Lunit (A328130) Stock Overview

Provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. More details

A328130 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

A328130 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Lunit Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lunit
Historical stock prices
Current Share Price₩38,150.00
52 Week High₩85,800.00
52 Week Low₩35,900.00
Beta1.32
1 Month Change-6.38%
3 Month Change-12.60%
1 Year Change-20.85%
3 Year Change186.30%
5 Year Changen/a
Change since IPO90.75%

Recent News & Updates

Some Confidence Is Lacking In Lunit Inc.'s (KOSDAQ:328130) P/S

Oct 31
Some Confidence Is Lacking In Lunit Inc.'s (KOSDAQ:328130) P/S

Is Lunit (KOSDAQ:328130) Using Too Much Debt?

Aug 18
Is Lunit (KOSDAQ:328130) Using Too Much Debt?

Recent updates

Some Confidence Is Lacking In Lunit Inc.'s (KOSDAQ:328130) P/S

Oct 31
Some Confidence Is Lacking In Lunit Inc.'s (KOSDAQ:328130) P/S

Is Lunit (KOSDAQ:328130) Using Too Much Debt?

Aug 18
Is Lunit (KOSDAQ:328130) Using Too Much Debt?

At ₩45,350, Is It Time To Put Lunit Inc. (KOSDAQ:328130) On Your Watch List?

Jun 14
At ₩45,350, Is It Time To Put Lunit Inc. (KOSDAQ:328130) On Your Watch List?

Lunit Inc. (KOSDAQ:328130) Shares Could Be 29% Above Their Intrinsic Value Estimate

May 16
Lunit Inc. (KOSDAQ:328130) Shares Could Be 29% Above Their Intrinsic Value Estimate

Is Lunit (KOSDAQ:328130) A Risky Investment?

Mar 31
Is Lunit (KOSDAQ:328130) A Risky Investment?

Lunit Inc.'s (KOSDAQ:328130) 28% Cheaper Price Remains In Tune With Revenues

Mar 07
Lunit Inc.'s (KOSDAQ:328130) 28% Cheaper Price Remains In Tune With Revenues

Is There Now An Opportunity In Lunit Inc. (KOSDAQ:328130)?

Mar 06
Is There Now An Opportunity In Lunit Inc. (KOSDAQ:328130)?

Subdued Growth No Barrier To Lunit Inc. (KOSDAQ:328130) With Shares Advancing 60%

Nov 20
Subdued Growth No Barrier To Lunit Inc. (KOSDAQ:328130) With Shares Advancing 60%

Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Apr 19
Here's Why We're Not At All Concerned With Lunit's (KOSDAQ:328130) Cash Burn Situation

Shareholder Returns

A328130KR Healthcare ServicesKR Market
7D-13.5%-5.6%3.4%
1Y-20.9%2.9%68.0%

Return vs Industry: A328130 underperformed the KR Healthcare Services industry which returned 2.9% over the past year.

Return vs Market: A328130 underperformed the KR Market which returned 68% over the past year.

Price Volatility

Is A328130's price volatile compared to industry and market?
A328130 volatility
A328130 Average Weekly Movement8.6%
Healthcare Services Industry Average Movement5.8%
Market Average Movement5.1%
10% most volatile stocks in KR Market10.7%
10% least volatile stocks in KR Market2.5%

Stable Share Price: A328130's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A328130's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2013298Beomseok Brandon Suhwww.lunit.io

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations and with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Lunit Inc. Fundamentals Summary

How do Lunit's earnings and revenue compare to its market cap?
A328130 fundamental statistics
Market cap₩1.16t
Earnings (TTM)-₩118.14b
Revenue (TTM)₩73.89b
15.1x
P/S Ratio
-9.4x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A328130 income statement (TTM)
Revenue₩73.89b
Cost of Revenue₩0
Gross Profit₩73.89b
Other Expenses₩192.03b
Earnings-₩118.14b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-4.05k
Gross Margin100.00%
Net Profit Margin-159.90%
Debt/Equity Ratio58.6%

How did A328130 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/14 14:50
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lunit Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun ChoiMacquarie Research
Hyun-soo HaYuanta Securities Korea Co., Ltd.